Beyond ‘Bad’ Cholesterol: New Clues To The Risk Of Heart Disease

TL;DR

For listenersOffer from Amazon

Turn quiet afternoons into listening time

• Thousands of audiobooks, podcasts and originals
• Listen on your phone, tablet or Echo — also offline
• Cancel anytime

Try Audible free →Free trial for new members

As an affiliate, we earn on qualifying purchases.Hide

A study led by researchers at Chalmers University of Technology identified overlapping blood-protein patterns in two types of fat-carrying particles, TRL and Lp(a), that may help explain some heart disease risk remaining after LDL cholesterol is lowered. The findings point to possible biological pathways for future research; they do not establish a new treatment or clinical test.

Researchers at Chalmers University of Technology have identified blood-protein patterns linked to two fat-carrying particles, TRL and Lp(a), that may help explain why some people remain at risk of heart disease even after their LDL cholesterol is lowered. The study, published in the European Heart Journal, suggests the particles may share inflammatory and blood-vessel effects, but it did not test a treatment or establish a test for clinical use.

The researchers analyzed nearly 3,000 blood proteins alongside genetic information and long-term health records. They examined three lipoproteins—LDL, triglyceride-rich lipoprotein (TRL) and lipoprotein(a) (Lp(a))—which can all carry cholesterol into artery walls. The analysis identified distinct protein patterns associated with the particles and with biological processes that could be involved in artery disease.

The protein patterns linked to TRL and Lp(a) overlapped. According to the study, proteins in these particles included signals associated with attracting immune cells, a process that may contribute to inflammation and changes in blood vessel walls. The researchers said the two particles may therefore affect some of the same vascular processes, although the study does not prove that those processes cause disease.

By comparison, the pattern associated with LDL was mainly linked to cholesterol buildup in artery walls. The findings build on earlier work by the same research group suggesting that counting harmful particles may predict future heart disease risk better than measuring cholesterol alone. The new analysis focuses on possible biological explanations, rather than testing a prevention strategy.

Risk Signals Beyond LDL

Lowering LDL cholesterol remains a central part of preventing heart attacks, but reaching a recommended LDL level does not remove all risk for everyone. The study offers biological clues about why other particles may matter and identifies shared processes researchers could investigate in future prevention research.

The distinction matters because the results do not mean that patients should change treatment or that a new protein panel is ready for routine care. Instead, the findings may help researchers determine whether measuring or targeting particular particle-related processes can add value to existing prevention. Cardiovascular disease causes nearly 17.9 million deaths worldwide each year, according to the World Health Organization, making better understanding of residual risk a significant research goal.

How the Particle Study Fits

Coronary heart disease develops when fatty material builds up in the blood vessels supplying the heart. High blood cholesterol is a major risk factor, and lowering LDL cholesterol substantially reduces heart attack risk. Still, some people develop coronary disease despite treatment bringing LDL to a recommended level.

TRL and Lp(a) are among the other particles that carry fats through the blood. The study authors describe them as potential contributors to remaining risk beyond LDL. Their work, titled “Apolipoprotein B-containing lipoproteins: distinct roles in atherosclerosis revealed by plasma proteomic profiling,” uses protein profiling to examine how these particles may affect the body. The results are an observational and biological investigation, not a clinical trial.

““For this study, we wanted to understand what happens beyond the accumulation of cholesterol in artery walls, whether different fat-carrying particles can damage the blood vessels differently and why the remaining risk of heart disease still occurs.””

— Jakub Morze, lead author and postdoctoral fellow at Chalmers University of Technology

From Protein Patterns to Patient Care

The study identifies associations and possible pathways; it does not show that the protein patterns directly cause heart disease. It also does not determine whether measuring these proteins improves risk prediction for individual patients or whether targeting them lowers heart attack risk. The report provides no evidence that a new protein test or treatment is ready for clinical use.

Further work is needed to establish how the findings apply across patient groups and whether they offer useful information beyond existing risk measures and treatments. The source material does not specify a timetable for those studies.

Testing the Prevention Potential

The researchers say the next step is to test whether measuring or targeting the identified biological processes can improve prevention alongside current care. That will require further research to determine whether the protein patterns can be used reliably and whether acting on them changes health outcomes.

For now, the study adds evidence about possible mechanisms behind risk beyond LDL, while leaving current prevention principles intact. Any potential clinical use remains a question for future studies, not a recommendation arising from this analysis.

Key Questions

What did the researchers find?

They found overlapping blood-protein patterns associated with TRL and Lp(a), two fat-carrying particles that may contribute to heart disease risk beyond LDL. The patterns point to possible shared inflammatory and blood-vessel processes.

Does the study show that these particles cause heart disease?

No. The study identifies associations and potential biological pathways. It does not prove that the patterns or particles directly cause disease.

Does this research change how LDL cholesterol should be treated?

No change to treatment follows from this study. The study leader said lowering LDL remains a cornerstone of prevention, and the analysis did not test a new treatment.

Can patients get a test based on these findings?

The study did not establish a protein test for clinical use. Researchers say further work is needed to learn whether measuring these processes can improve prevention.

Source: rss